Belzutifan Ireland – NCPE assessment
The NCPE has updated their website this week with the outcome of its assessment of Belzutifan, which can be viewed here: Belzutifan (Welireg®). HTA ID: 25020 | National Centre for …
belzutifan
An Insightful VHL Patient Support Day – Sheffield, May 2025
We were thrilled to welcome over 30 attendees to our VHL Patient Support Day, held at the Mercure Sheffield Parkway Hotel this May. It was a day filled with connection, …
Capturing the ‘real-world’ experience of belzutifan
VHL UK Ireland has granted £41,000 to Crick Insitute Researchers – Dr. Scott Shepherd, Prof. Samra Turajlic and Prof. William Drake Background Belzutifan is transforming the management of individuals with …
Belzutifan – Frequently Asked Questions
These FAQs are published by VHL UK/Ireland in partnership with Dr Scott Shepard. Last Updated: September 2025 1. What is VHL? Von Hippel-Lindau disease (VHL) is a devastating, rare, life-long, …
GAME-CHANGING DRUG, BELZUTIFAN (WELIREG), RECOMMENDED WITH MANAGED ACCESS FOR VON HIPPEL-LINDAU PATIENTS IN ENGLAND
VHL UK/Ireland is pleased to announce that on the 5th September 2024, the National Institute of Health & Care Excellence (NICE) published its Final Draft Guidance for NHS England with …
Study of molecular mechanisms involved when VHL patients undergo belzutifan (Welireg) therapy.
VHL UK Ireland has granted £35,000 to Professor William Drake Consultant Physician/Professor of Clinical Endocrinology at St Bartholomew’s Hospital. An overview from Professor Drake:“Our research endeavours focus on the intricate …
